Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
Takeaways: The positive reimbursement recommendation from Canada’s drug agency moves Leqembi closer to public funding for early Alzheimer’s disease, which can significantly expand the ...
Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
